SGLT2 Inhibitors Market to Reach $34.6B by 2036

Got story updates? Submit your updates here. ›

The global SGLT2 inhibitors market is projected to grow from $19 billion in 2026 to $34.6 billion by 2036, at a CAGR of 6.2%. This expansion reflects the shift in clinical guidelines, as SGLT2 inhibitors are emerging as a versatile treatment for conditions beyond just Type 2 Diabetes, including heart failure and chronic kidney disease.

Why it matters

SGLT2 inhibitors are no longer viewed solely as glucose-lowering agents, but as a foundational pillar of preventative cardiology and nephrology. By facilitating the excretion of glucose and sodium, these inhibitors offer unique hemodynamic benefits that protect vital organs from long-term systemic stress.

The details

Regulatory bodies have expanded the indications for SGLT2 inhibitors, allowing for their use in heart failure and chronic kidney disease management. A significant trend is the rise of fixed-dose combinations, which simplify patient regimens and improve adherence. Drugs like Dapagliflozin and Empagliflozin have become widely adopted, driven by real-world evidence confirming their long-term safety and efficacy.

• The global SGLT2 inhibitors market is projected to grow from $19 billion in 2026 to $34.6 billion by 2036.
• This represents a Compound Annual Growth Rate (CAGR) of 6.2% over the forecast period.

What’s next

The expanded indications for SGLT2 inhibitors, including in heart failure and chronic kidney disease, are expected to drive continued growth in the market.